Work

Case Report: Severe Pneumocystis jirovecii pneumonia following zuberitamab treatment in autoimmune hemolytic anemia

Year: 2025

Type: article

Abstract: The pathogenesis of autoimmune hemolytic anemia (AIHA) remains incompletely understood, typically associated with immune dysfunction and the production of autoantibodies. Zuberitamab, a novel anti-CD20 monoclonal antibody, represents an important therapeutic strategy for managing autoimmune diseases. Here, we present the first case of a patient diagnosed with AIHA who developed severe immunosuppression, lymphopenia, and B-cell depletion following zuberitamab treatment, ultimately resulting in severe Pneumocystis jirovecii pneumonia(PJP). This case highlights the complexities of B-cell-targeted immunotherapy and underscores the necessity of close monitoring of immune status in patients receiving zuberitamab or other targeted immunotherapies to mitigate the risk of severe immune-related adverse events.

Source: Frontiers in Immunology

DOI: 10.3389/fimmu.2025.1546571

Authors: Qian Yang, Peng Ding, Yu-xiang Liu, Kai-chen Zhang, Pei-yang Gao

Institution: Chengdu University of Traditional Chinese Medicine

Language: English

Topic: Pneumocystis jirovecii pneumonia detection and treatment

Subfield: Epidemiology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: gold

Estimated APC paid: $3,801